Abstract: Described herein are methods for determining the prognosis of a patient diagnosed with Acute Lymphoblastic Leukemia (ALL), and particularly determining the risk of disease relapse following standard treatment. Also described are systems of treatment that are directed by a health care provider, and which include the described prognostic methods and the treatments recommended for patients determined to have a specific relapse risk.

Abstract: Described herein is the correlation between miR-451 expression and the increased benefit of a treatment modality of solid tumors that effects miR-451 modulated metabolic pathways. Such modalities include NAMPT inhibitors and/or PARP inhibitors. Also described herein are methods for treatment of solid tumors that include determining whether treatment of the tumor would benefit from inhibition of NAMPT and/or PARP and if so, treating the patient afflicted with the tumor with NAMPT and/or PARP inhibitors.

Abstract: The present invention relates to prognostic methods and kits for the assessment and monitoring of relapse-free or disease-free survival of ALL patients. The detection is based on the use of detecting nucleic acids, specific for determination of the expression of at least one of miR-151-5p and miR-451 in a test sample. The invention thereby also provides methods and kits for monitoring and early diagnosis of cancerous disorders associated with low miR-151-5p and/or miR-451 expression, specifically ALL, and appropriate associated treatments thereof.

Abstract: Described herein are methods for determining the prognosis of a patient diagnosed with Acute Lymphoblastic Leukemia (ALL), and particularly determining the risk of disease relapse following standard treatment. Also described are systems of treatment that are directed by a health care provider, and which include the described prognostic methods and the treatments recommended for patients determined to have a specific relapse risk.

Abstract: Provided herein is the use of miR-451 as a biomarker in prognosis of anti-ALL treatment modalities, in early diagnosis of ALL relapse risk, and/or in identifying an ALL patient that can benefit from a treatment modality that affects one or more miR-451-related metabolic pathways.

Abstract: Described herein are methods of cancer diagnosis through monitoring the presence and activity of the KANSL1 gene, and particularly the effects of KANSL1 overexpression on specific histone acetylation. Cancer treatment with histone acetyltransferase inhibitors and deacetylase agents is also described.

Abstract: Described herein are methods for determining the prognosis of a patient diagnosed with Acute Lymphoblastic Leukemia (ALL), and particularly determining the risk of disease relapse following standard treatment. Also described are systems of treatment that are directed by a health care provider, and which include the described prognostic methods and the treatments recommended for patients determined to have a specific relapse risk.

Abstract: Provided herein are compositions for treatment of Acute Lymphoblastic Leukemia (ALL) and methods of their use, including inhibiting ALL relapse. Further provided herein are systems of treatment that are directed by a health care provider, and which combine prognostic methods for determining ALL relapse and the described treatments.

Abstract: The present invention relates to prognostic methods and kits for the assessment and monitoring of relapse-free or disease-free survival of ALL patients. The detection is based on the use of detecting nucleic acids, specific for determination of the expression of at least one of miR-151-5p and miR-451 in a test sample. The invention thereby also provides methods and kits for monitoring and early diagnosis of cancerous disorders associated with low miR-151-5p and/or miR-451 expression, specifically ALL, and appropriate associated treatments thereof.

Abstract: The present invention relates to prognostic methods and kits for the assessment and monitoring of relapse-free or disease-free survival of ALL patients. The detection is based on the use of detecting nucleic acids, specific for determination of the expression of at least one of miR-151-5p and miR-451 in a test sample. The invention thereby also provides methods and kits for monitoring and early diagnosis of cancerous disorders associated with low miR-151-5p and/or miR-451 expression, specifically ALL.

Abstract: Embodiments of the invention are directed to a system for treatment of material by microwave radiation. The system may include a casing, a waveguide connected to the casing to conduct microwave radiation from a radiation source into the casing, an inner container transparent to microwave radiation, the container having an inlet to receive material to be treated and an outlet to discharge treated material and a transport unit to carry the treated material.

Abstract: Provided is a novel method and system to separate magnetically non-susceptible impurities from coal intended for combustion, and it includes the removal of such impurities together with magnetically susceptible impurities that are collocated within the same lump of coal, prior to the combustion of the coal, by the use of the magnetic properties of the magnetically susceptible impurities. The described subject matter is based on the fact that the former impurities are normally collocated in the same lumps of coal as the latter, especially as far as pyrite and cinnabar are concerned, provided the lumps have not been liberated, in particular, they meet the requirement that at least 50% by mass of the coal lumps should be at least 2 mm in maximum dimension.

Abstract: The present invention provides a method for assessing the prognosis of Ewing's Sarcoma patients comprising determining the expression pattern of a defined set of genes in tumor material obtained from said patients, and assigning said expression pattern to either a good prognosis or poor prognosis group.

Abstract: Method for managing electric power generated during periods of low demand, in an electric power market where consumption of electric power exhibits periods of different demands. The method includes upgrading solid fossil fuel by electromagnetic radiation (EMR) upgrading during the periods of low demand, storing and utilization of the upgraded fuel. Fuel utilization may include burning for electric power generation during periods of high demand, burning in another heat-consuming industrial process, or trading the fuel with another business entity. The EMR upgrading used in the method includes reducing the inherent moisture content in the upgraded fossil fuel at least in half.

Abstract: Disclosed is a novel form of particulate precipitated aragonite calcium carbonate and a novel process for producing it.

Abstract: Disclosed is a novel form of particulate precipitated aragonite, and a novel process for producing it.

Abstract: Disclosed is a novel form of particulate precipitated aragonite, and a novel process for producing it.

Abstract: Disclosed is a novel form of particulate precipitated aragonite, a novel process for producing it and compositions containing it.